TITLE:
Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice
AUTHORS:
José M. García-Mediero, Francisco Sánchez-Ballester, Daniel Arumi, Isabel Lizarraga
KEYWORDS:
Fesoterodine, Flexible-Dose, Overactive Bladder, Solifenacin
JOURNAL NAME:
Open Journal of Urology,
Vol.6 No.6,
June
14,
2016
ABSTRACT: Aim: To explore in daily clinical practice
the evolution in time of the fesoterodine and solifenacin dose pattern and
assess the therapeutic benefit provided by the highest dose of these anti-muscarinics.
Patients and Methods: This was a post-hoc analysis of data from an
observational, cross-sectional, retrospective and multicenter study. Adult
patients diagnosed with over active bladder (OAB) who initiated fesoterodine or
solifenacin treatment were included. Data on the prescribed treatment and dose,
change of dose, reasons for switching and treatment benefit were recorded.
Results: A total of 828 subjects were analyzed (262 receiving solifenacin and
566 fesoterodine). Most subjects were women with a mean time since diagnosis of
more than one year and aged around 60 years old. The majority of patients
initiated the OAB treatment with the lowest available dose (64% fesoterodine
vs. 77% solifenacin). At the follow-up visit 54% of the fesoterodine group and
66% of the solifenacin opted for dose escalation. At the study visit, 70.1%
fesoterodine vs. 43.3% solifenacin remained on the highest dose. A
significantly greater proportion of subjects receiving fesoterodine 8 mg,
reported higher improvement in terms of both patient-reported-treatment benefit
and clinical global impression compared with solifenacin 10 mg (p